Fig 3.

Kaplan-Meier overall survival estimates and Cox regression survival analysis for multigene classifiers (MGCs) within the independent validation cohort. (A) Histopathologically hormone responsive (defined as estrogen receptor [ER] positive and progesterone receptor [PgR] positive) group stratified by MGC hormone responsive classification (concordant [blue curve] or discordant [gold curve] to histopathology) within the subgroup of patients who received (left) no adjuvant systemic therapy, (middle) endocrine therapy alone, or (right) chemotherapy with or without trastuzumab or endocrine therapy. (B) Human epidermal growth factor receptor 2 [HER2]–negative histopathology group stratified by HER2 MGC for the same three treatment subgroups as in A. (C) Ki67-high histopathology group stratified by Ki67 MGC for the same three treatment subgroups as in A. (D) Nottingham histologic grade (NHG) combined grade [G] 1 and G2 histopathology group stratified by NHG MGC for the same three treatment subgroups as in A. In each Kaplan-Meier plot, the histopathology to MGC concordant tumor cases are plotted in blue, the discordant tumor cases are plotted in gold, the log-rank P value is given, and the hazard ratio (HR) for discordant-versus-concordant result is given with a 95% CI and after multivariable (MV) Cox regression adjustment. Covariables included in the MV analysis were age at diagnosis, lymph node status, tumor size, and the variables denoted by the following symbols: †, ER, PgR, and NHG; ‡, ER, PgR, HER2, and NHG; §, HER2 and NHG; #, ER, PgR, and HER2.